Diabetic cardiomyopathy: a clinical entity or a cluster of molecular heart changes?

European Journal of Clinical Investigation

Volumn 46, Issue 11, 2016, Pages 947-953

  Mizamtsidi, Maria ^a   Paschou, Stavroula A ^a   Grapsa, Julia ^b   Vryonidou, Andromachi ^a  

^a RED CROSS HOSPITAL   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiomyopathy; cardiovascular; diabetes; hyperglycemia; myocardium; oxidative stress

Indexed keywords

COLLAGEN; FATTY ACID; GLUCOSE; REACTIVE OXYGEN METABOLITE;

BLOOD GLUCOSE MONITORING; CARDIAC AUTONOMIC NEUROPATHY; CELL DEATH; DIABETIC CARDIOMYOPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIASTOLIC DYSFUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MITOCHONDRION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID STORAGE; LIPOTOXICITY; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC DYSFUNCTION; COMPLICATION; DIABETIC CARDIOMYOPATHIES; DIABETIC NEPHROPATHY; DIASTOLE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HYPERINSULINISM; HYPERTROPHY, LEFT VENTRICULAR; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

CELL DEATH; COLLAGEN; DIABETIC CARDIOMYOPATHIES; DIABETIC NEPHROPATHIES; DIASTOLE; ENDOMYOCARDIAL FIBROSIS; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPERTROPHY, LEFT VENTRICULAR; LIPID METABOLISM; MITOCHONDRIA, HEART; MITOCHONDRIAL DISEASES; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84992549225     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12673     Document Type: Review

References (70)

1. Kovacic JC, Castellano JM, Farkouh ME, Fuster V. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. Endocrinol Metab Clin North Am 2014;43:41–57.
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213–23.
3. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595–602.
4. Johnson EJ. Diabetic Cardiomyopathy: Phenotypes, Mechanisms, and Therapeutic Targets. Washington, DC: Washington State University; 2015.
5. Boudina S. Clinical manifestations of diabetic cardiomyopathy. Heart Metab 2009;45:10–4.
6. Aneja A, Tang WW, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008;121:748–57.
7. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85–9.
8. Rerkpattanapipat P, D'Agostino RB, Link KM, Shahar E, Lima JA, Bluemke DA et al. Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes implications for left ventricular hypertrophy from the multi-ethnic study of atherosclerosis. Diabetes 2009;58:946–53.
9. Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco RL, Homma S et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008;101:1787–91.
10. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2016;90:84–93.
11. Kawaguchi M, Techigawara M, Ishihata T, Asakura T, Saito F, Maehara K et al. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels 1997;12:267–74.
12. Fischer VW, Barner HB, Larose LS. Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum Pathol 1984;15:1127–36.
13. Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1985;1:43–7.
14. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848–55.
15. Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R et al. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 1993;46:32–6.
16. Gonzalez-Vilchez F, Ayuela J, Ares M, Pi J, Castillo L, Martin-Duran R. Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int J Cardiol 2005;101:53–8.
17. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977;60:885.
18. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008;52:1793–9.
19. Schannwell C, Schneppenheim M, Perings S, Plehn G, Strauer B. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 2002;98:33–9.
20. Beljic T, Miric M. Improved metabolic control does not reverse left ventricular filling abnormalities in newly diagnosed non-insulin-dependent diabetes patients. Acta Diabetol 1994;31:147–50.
21. Di Bonito PD, Cuomo S, Moio N, Sibilio G, Sabatini D, Quattrin S et al. Diastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short duration. Diabetic Med 1996;13:321–4.
22. Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004;93:870–5.
23. Shivalkar B, Dhondt D, Goovaerts I, Van Gaal L, Bartunek J, Van Crombrugge P et al. Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol 2006;97:77–82.
24. Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH. Screening for heart disease in diabetic subjects. Am Heart J 2005;149:349–54.
25. Yu C-M, Lin H, Yang H, Kong S-L, Zhang Q, Lee SW-L. Progression of systolic abnormalities in patients with “isolated” diastolic heart failure and diastolic dysfunction. Circulation 2002;105:1195–201.
26. Scognamiglio R, Avogaro A, Casara D, Crepaldi C, Marin M, Palisi M et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998;31:404–12.
27. Ha J-W, Lee H-C, Kang E-S, Ahn C-M, Kim J-M, Ahn J-A et al. Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography. Heart 2007;93:1571–6.
28. Johnson PC, Doll SC, Cromey DW. Pathogenesis of diabetic neuropathy. Ann Neurol 1986;19:450–7.
29. Abel ED, Graveleau C, Betuing S, Pham M, Reay PA, Kandror V et al. Regulation of insulin-responsive aminopeptidase expression and targeting in the insulin-responsive vesicle compartment of glucose transporter isoform 4-deficient cardiomyocytes. Mol Endocrinol 2004;18:2491–501.
30. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002;109:629–39.
31. Westermeier F, Riquelme J, Pavez M, Garrido V, Díaz A, Verdejo HE et al. New molecular insights of insulin in diabetic cardiomyopathy. Front Physiol 2016;7:125.
32. Fu Q, Xu B, Liu Y, Parikh D, Li J, Li Y et al. Insulin inhibits cardiac contractility by inducing a Gi-biased β2-adrenergic signaling in hearts. Diabetes 2014;63:2676–89.
33. Díaz A, Humeres C, González V, Gómez MT, Montt N, Sanchez G et al. Insulin/NFκB protects against ischemia-induced necrotic cardiomyocyte death. Biochem Biophys Res Commun 2015;467:451–7.
34. Riehle C, Wende AR, Sena S, Pires KM, Pereira RO, Zhu Y et al. Insulin receptor substrate signaling suppresses neonatal autophagy in the heart. J Clin Invest 2013;123:5319–33.
35. Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metabol 2014;25:128–37.
36. Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 2008;57:2924–32.
37. Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasik W, Piwowarska W. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007;28:2465–71.
38. Tang Y, Li G. Chronic exposure to high glucose impairs bradykinin-stimulated nitric oxide production by interfering with the phospholipase-C-implicated signalling pathway in endothelial cells: evidence for the involvement of protein kinase C. Diabetologia 2004;47:2093–104.
39. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–20.
40. Schaffer SW, Jong CJ, Mozaffari M. Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited. Vascul Pharmacol 2012;57:139–49.
41. Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage. J Diabetes Investig 2014;5:623–34.
42. Willemsen S, Hartog JW, Hummel YM, van Ruijven MH, van der Horst IC, van Veldhuisen DJ et al. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail 2011;13:76–82.
43. Cesario DA, Brar R, Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006;35:601–10.
44. Falcão-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2012;17:325–44.
45. Park T-S, Hu Y, Noh H-L, Drosatos K, Okajima K, Buchanan J et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008;49:2101–12.
46. Yazaki Y, Isobe M, Takahashi W, Kitabayashi H, Nishiyama O, Sekiguchi M et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 1999;81:153–9.
47. Aon MA, Foster DB. Diabetic cardiomyopathy and the role of mitochondrial dysfunction: novel insights, mechanisms, and therapeutic strategies. Antioxid Redox Signal 2015;22:1499–501.
48. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003;107:3040–6.
49. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998;40:239–47.
50. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A et al. Myocardial cell death in human diabetes. Circ Res 2000;87:1123–32.
51. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients reversal by chronic angiotensin II type 1A receptor blockade. Circ J 2007;71:524–9.
52. Peti-Peterdi J, Kang JJ, Toma I. Activation of the renal renin–angiotensin system in diabetes – new concepts. Nephrol Dial Transplant 2008;23:3047–9.
53. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9.
54. Symeonides P, Koulouris S, Vratsista E, Triantafyllou K, Ioannidis G, Thalassinos N et al. Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. Eur Heart J Cardiovasc Imaging 2007;8:480–6.
55. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014;5:17–39.
56. Karayannis G, Giamouzis G, Cokkinos DV, Skoularigis J, Triposkiadis F. Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Rev Cardiovasc Ther 2014;10:747–65.
57. Mytas DZ, Stougiannos PN, Zairis MN, Foussas SG, Pyrgakis VN, Kyriazis IA. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J Diabetes Complications 2009;23:273–82.
58. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47:693–700.
59. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy – fact or fiction? Herz 2011;36:102–15.
60. Maulik N. Diabetes Associated Cardiomyopathy and Cell Therapy. Cardiovascular Diseases: Nutritional and Therapeutic Interventions. Farmington, CT: CRC Press; 2013: pp. 211–34.
61. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Karatzas ND. Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy A radionuclide ventriculography study. Diabetes Care 2003;26:1955–60.
62. Kahn JK, Zola B, Juni JE, Vinik AI. Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy. J Am Coll Cardiol 1986;7:1303–9.
63. Karayannis G, Giamouzis G, Alexandridis E, Kamvrogiannis P, Butler J, Skoularigis J et al. Prevalence of impaired coronary flow reserve and its association with left ventricular diastolic function in asymptomatic individuals with major cardiovascular risk factors. Eur J Cardiovasc Prev Rehabil 2011;18:326–33.
64. Mustonen J, Uusitupa M, Länsimies E, Vainio P, Laakso M, Pyörälä K. Autonomic nervous function and its relationship to cardiac performance in middle-aged diabetic patients without clinically evident cardiovascular disease. J Intern Med 1992;232:65–72.
65. Yokoyama I, Ohtake T, S-i Momomura, Yonekura K, Woo-Soo S, Nishikawa J et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes 1998;47:119–24.
66. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 2001;23:45–55.
67. Triposkiadis F, Giamouzis G, Butler J. The importance of managing diabetes correctly to prevent heart failure. Expert Rev Cardiovasc Ther 2011;9:257–9.
68. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747–62.
69. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57:660–71.
70. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 2016;12:144–53.